Healthcare investment company ARCHIMED鈥檚 affiliate is set to acquire ZimVie, a life sciences company focusing on the dental implant market, for an enterprise value of around $730m.
According to the definitive agreement signed by the companies, the stockholders of ZimVie will be entitled to a $19.00 cash payment for each outstanding share when the transaction is finalised.
The price per share signifies a premium of 99% to ZimVie’s 90-day volume-weighted average share price, which stands at $9.57.
ZimVie鈥檚 Board of Directors granted unanimous approval for the transaction, anticipated to be finalised by the end of this year.
This is contingent on standard closing conditions, including ZimVie’s stockholders’ and regulatory bodies’ approval. Notably, the agreement is not dependent on financing.
ARCHIMED managing partner Andr茅-Michel Ballester said: 鈥淲e鈥檙e excited to partner with ZimVie and its talented team. The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFollowing the acquisition, ZimVie is set to become a private entity. Additionally, ZimVie, with Centerview Partners’ assistance, may seek alternative proposals for a 40-day period ending on 29 August 2025, although there is no certainty of a superior offer emerging.
ZimVie CEO and board chairman Vafa Jamali said: 鈥淭his transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years.
鈥淧artnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.鈥�
Centerview Partners is acting as ZimVie’s exclusive financial adviser, with Cravath, Swaine & Moore as its legal adviser.
Meanwhile, UBS Investment Bank and Latham & Watkins are serving as ARCHIMED鈥檚 financial and legal advisers, respectively.
In 2023, the US Food and Drug Administration (FDA) cleared ZimVie鈥檚 spinal fixation system, Vital, for use with Brainlab鈥檚 surgical imaging, planning, and navigation tools.
